CD8A and hepatocellular carcinoma: Zhu et al. reported that hindering CSF-1 signalling with CSF-1R inhibitors elicited a reduction in TAMs and an increase in CD8+ T-cell infiltration, sensitizing an HCC mouse model to anti-PD-L1 therapy [158].